TABLE 2.
Baseline Characteristics of Patient Population (n = 1562)
| Anastomotic Leakage (n = 132) | No Anastomotic Leakage (n = 1430) | ||||
| Variable | Missing | Missing | P Value | ||
| Sex (male) | 81 (62%) | 718 (50%) | 0.009 | ||
| Age (yrs)∗ | 71 (21–91) | 68 (23–95) | 0.162 | ||
| < 70 | 64 (48%) | 759 (53%) | |||
| ≥ 70 | 68 (52%) | 663 (47%) | |||
| Body mass index ≥ 30 kg/m2 | 27 (20%) | 241 (17%) | 0.212 | ||
| ASA classification | 0.009 | ||||
| < 3 | 87 (66%) | 1075 (76%) | |||
| ≥ 3 | 45 (34%) | 343 (24%) | |||
| Diabetes mellitus | 29 (22%) | 204 (14%) | n = 12 | 0.017 | |
| Intoxications | |||||
| Current smoker | 18 (14%) | n = 5 | 169 (12%) | n = 70 | 0.326 |
| Pack years ≥ 15 yrs | 40 (31%) | n = 4 | 301 (22%) | n = 43 | 0.011 |
| Alcohol intake ≥ 3 units/d | 14 (10%) | n = 4 | 121 (9%) | n = 2 | 0.244 |
| Steroid use (excl. inhalers) | 4 (4%) | 36 (3%) | n = 14 | 0.449 | |
| Disease | n = 6 | 0.157 | |||
| Malignant | 113 (85%) | 1163 (82%) | |||
| Benign | 19 (15%) | 261 (18%) | |||
| Diagnosed by screening program | 48 (42%) | n = 18 | 476 (39%) | n = 238 | 0.361 |
| Neoadjuvant therapy | n = 3 | n = 74 | 0.195 | ||
| None | 111 (86%) | 1192 (88%) | |||
| 5 × 5 radiotherapy | 10 (8%) | 92 (7%) | |||
| Chemotherapy | 3 (2%) | 30 (2%) | |||
| Chemoradiotherapy | 5 (4%) | 42 (3%) | |||
| Distance of tumor from AV <15 cm | 37 (29%) | n = 6 | 267 (19%) | n = 22 | 0.005 |
| Pathological TNM stage | n = 21 | n = 284 | 0.158 | ||
| I (T1–2N0M0) | 52 (47%) | 407 (36%) | |||
| II (T3–4N0M0) | 23 (21%) | 324 (28%) | |||
| III (T1–4N1–2M0) | 27 (24%) | 352 (31%) | |||
| IV (T1–4N1–2M1) | 9 (8%) | 63 (6%) | |||
Data are presented as number (%) unless stated otherwise.
∗
Data are presented as medians (range).
AV indicates anal verge. A P < 0.05 was considered statistically significant.
Bold numbers are statistically significant.